Market Research Logo

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Overview
Therapeutics Development
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Stage of Development
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Therapy Area
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Indication
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
Karyopharm Therapeutics, Inc.
Stemline Therapeutics, Inc.
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
KPT-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-276 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-8602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Projects
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Featured News & Press Releases
Jul 27, 2016: Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
Jul 27, 2016: Karyopharms Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
Jun 16, 2016: Karyopharm Outlines Key Selinexor Clinical Development Achievements
Jun 10, 2016: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting
Jun 06, 2016: Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma
May 19, 2016: Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
May 18, 2016: Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial
Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury
Mar 31, 2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus
Mar 16, 2016: Karyopharm to Present Data on Oncology drug Selinexor (KPT-330) at the 2016 American Association for Cancer Research Annual Meeting
Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting
Mar 04, 2016: Karyopharm’s Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology
Jan 19, 2016: Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple Myeloma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Pipeline by Stemline Therapeutics, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016’, provides in depth analysis on Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted pipeline therapeutics.

The report provides comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
    • The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;